Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Community Stories
DMD
DM1
Careers
Investors
News
Contact
Mechanistic characterization of enhanced delivery oligonucleotide (EDO) platform
Post navigation
Previous:
Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1
Next:
Nonclinical in vitro and in vivo data demonstrated low immunogenicity risk and favorable of PGN-EDO51 for the treatment of DMD
